Jeffrey Allen Miller, Halliburton's director, president and chief executive officer, sold 171,200 shares of the company's common stock on January 23, 2026, at a per-share price of $34.96, resulting in proceeds of $5.98 million. On the same day he exercised options to acquire 171,200 shares at an exercise price of $31.44, for an aggregate exercise cost of $5.38 million.
The sale was carried out under a pre-established Rule 10b5-1 trading plan that Miller adopted on February 13, 2025. After completing the sale, Miller's direct ownership in Halliburton stood at 1,101,243.02 shares.
Halliburton shares were trading close to their 52-week high of $35.55 at the time of the transaction, and the stock has exhibited notable momentum, rising more than 53% over the past six months. The company is currently valued at $28.67 billion, trades at a price-to-earnings ratio of 22.75 and yields approximately 2% in dividends, having maintained dividend payments for 55 consecutive years according to available data.
Analyst context and available research
Analyst price targets for Halliburton span a wide range, from $28 on the low end to $46.48 on the high end. Additionally, there are 11 further analyst tips and pieces of comprehensive analysis covering Halliburton, including a financial health rating and a Pro Research Report that forms part of broader coverage across over 1,400 U.S. equities.
Recent financial results that preceded the updates
Halliburton reported fourth-quarter 2025 adjusted earnings per share of $0.69, surpassing both UBS's estimate of $0.56 and the Street consensus of $0.55. Revenue for the quarter came in at $5.66 billion, above UBS's forecast of $5.43 billion and other analysts' projection of $5.41 billion.
In the wake of those results, several firms revised their price targets. BMO Capital raised its target to $39 from $36 while retaining a Market Perform rating. RBC Capital increased its target to $38, citing stronger-than-expected performance in the Completion and Production segment. Evercore ISI set its target at $36, noting an improved margin outlook. At the same time, UBS and Piper Sandler held onto Neutral ratings with price targets of $32 and $30, respectively. These updates reflect differing interpretations of Halliburton's recent operating results and near-term margin trajectory.
Implications and market setting
The insider transaction occurred as the company posted quarterly results that outpaced select analyst forecasts and as the stock hovered near its annual high. The combination of an option exercise and an immediate sale under a prearranged plan is consistent with standard executive equity-management practices. Market participants continue to parse the earnings beat, the revenue overperformance and the analyst target revisions when assessing Halliburton's outlook.
Note: The article reports the transaction details, company metrics, analyst ranges and recent earnings and revenue figures as provided. It does not infer future stock performance or additional motives beyond the stated facts.